Aclarion

Aclarion Equity

The The Equity of Aclarion (ACON) as of Nov 2, 2026 is 12.84 M USD. In the previous year, The Equity was 970,057.00 USD — a change of 1,223.13% (higher).

Equity

12.84 MUSD

YoY

1,223.13%

Last updated:

In 2025, Aclarion's equity was 12.84 M USD, a 1,223.13% increase from the 970,057.00 USD equity in the previous year.

The Aclarion Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-1.70 M USD
Jan 1, 2020
-7.08 M USD
Jan 1, 2021
-5.73 M USD
Jan 1, 2022
2.23 M USD
Jan 1, 2023
-727,995.00 USD
Jan 1, 2024
970,057.00 USD
Jan 1, 2025
12.84 M USD
The Aclarion Equity history
YEAREquityYoY
12.84 MUSD+1,223.13%
970,057.00USD-233.25%
-727,995.00USD-132.70%
2.23 MUSD-138.85%
-5.73 MUSD-19.12%
-7.08 MUSD+316.21%
-1.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aclarion Stock analysis

What does Aclarion do? Aclarion, Inc. generates revenue through its proprietary biomarker technology and signal processing software, which transforms raw Magnetic Resonance Spectroscopy (MRS) data into metabolic biomarkers for clinical use. The company's products are utilized by physicians to differentiate between painful and nonpainful lumbar spine discs, leveraging augmented intelligence in post-processing algorithms to quantify biomarker data and produce individualized ratio metrics against normative datasets. The firm targets healthcare providers focused on chronic low back pain treatment, offering solutions that optimize clinical decision-making through metabolic analysis. Aclarion's technology is centered on Magnetic Resonance Spectroscopy (MRS) and its proprietary biomarker, designed to assist physicians in determining disc-related pain in the lumbar spine. The company's signal processing software and expert system convert raw spectral MRS data into clear, actionable biomarkers, enabling tailored treatment approaches for chronic low back pain patients. By focusing exclusively on this clinical application, Aclarion serves a specialized segment of healthcare providers seeking advanced diagnostic tools for spinal conditions. Aclarion is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Aclarion's Equity

Aclarion's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Aclarion's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Aclarion's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Aclarion's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Aclarion’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Aclarion stock

The Equity of Aclarion is 12.84 M USD in 2025.

The Equity of Aclarion changed from 970,057.00 USD to 12.84 M USD, representing a 1,223.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Aclarion since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Aclarion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aclarion

All Key Metrics — Aclarion